Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables growth accelerates

Q2 FY2026 accounts payables of $38.18M rose 261.0% year over year, ahead of the +177.5% change in trailing-twelve-month accounts payables. Sequentially, it fell 33.3% from the prior quarter. Over 3 fiscal years it compounded at +87.2% a year.

Context

  • Accounts payables amounted to 9.6% of revenue in FY2025, down 2.4 pp from a year earlier.
  • Accounts payables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +261.0% holds above the trailing-twelve-month pace of +177.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$38.18M-33.3% QoQ
Last fiscal yearDec 2025
$50.1M+24.3% YoY
LTMJun 2026
$123.22M+177.5% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+261.0%——
1 year+24.3%——
3-year CAGR+87.2%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
50.1M USD
Year-over-year change
+24.3%
4-year CAGR
+21.9%

Accounts Payables vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's LTM Jun 2026 accounts payables of $123.22M is the largest of the 8 companies compared; the peer median is $399K.
  • Its year-over-year change of +177.5% is the 2nd highest of 8, against a peer median of +116.9%.
  • Accounts payables amounts to 19.9% of revenue for MIRM, versus a peer median of 0.6%.
MIRM Competitors Peer median
Accounts Payables for MIRM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$123.22M +177.5%+87.2%19.9%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$15.45M +166.8%-33.0%2.3%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$6.65M -122.9%+29.1%0.5%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$2.72M +151.1%—0.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.19M -26.1%-1.7%4.8%
ALTAltimmune, Inc.LTM Mar 2026$453K +116.9%-3.3%1258.3%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$426K -118.1%-20.2%0.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$399K +1230.0%-34.4%0.6%
Peer median (excluding MIRM) $399K+116.9%-11.7%0.6%

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.99M)(135.67M)(163.42M)(87.94M)(23.36M)
Depreciation & Amortization975K3.24M10.83M23.63M24.24M
Deferred Income Tax595K(6.58M)000
Stock-Based Compensation23.09M27.01M35.02M48.44M71.42M
Change in Working Capital16.98M(21.05M)(22.64M)22.59M(19.72M)
Accounts Receivables0(20.73M)(43.97M)(11.43M)(48.06M)
Inventory(495K)(3.45M)(4.39M)(3.17M)(8.45M)
Accounts Payables22.66M7.64M30.78M40.31M50.1M
Other Working Capital(5.18M)(4.51M)(5.05M)(3.13M)(13.32M)
Other Non-Cash Items(90.41M)12.91M69.26M3.6M3.24M
Operating Cash Flow(132.76M)(120.14M)(70.94M)10.33M55.83M
Capital Expenditures(19.02M)(278K)(20.11M)(993K)(954K)
Acquisitions (Net)(19M)(7.98M)(212.76M)00
Purchases of Investments(198.03M)(132.32M)(27.33M)(89.03M)(97.43M)
Sales of Investments157.6M140.3M153M19.89M74.43M
Other Investing Activities127M7.98M(20M)(20M)0
Investing Cash Flow48.55M7.7M(107.2M)(90.13M)(23.95M)
Debt Repayment00305.3M00
Common Stock Issued6.91M107.37M216.68M17.7M40.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities66.55M1.72M(185.39M)00
Financing Cash Flow73.47M109.09M336.6M17.7M40.14M
Effect of Forex Changes(1K)12K(133K)(1.3M)3.22M
Net Change in Cash(10.75M)(3.34M)158.32M(63.4M)75.24M
Free Cash Flow(151.78M)(120.41M)(91.05M)9.33M54.87M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.